Proposed monographs for omission from the BP 2026

Published 04 February 2025

The British Pharmacopoeia Commission is continuing to ensure that the publication remains relevant and comprehensive. As part of this work, several monographs included in the current edition of the British Pharmacopoeia have been proposed for omission due to the lack of UK based Marketing Authorisation Holders and/or low usage within the UK. 


The monographs proposed for omission from the BP 2026 are:

  • Bumetanide Injection
  • Senna Liquid Extract
  • Standardised Senna Granules

The British Pharmacopoeia is used in many countries and we welcome feedback from national and international stakeholders regarding the proposed omissions. Monographs omitted from the BP 2026 publications will remain available within the BP Archive, which is accessible via the BP Online publication. Such monographs continue to remain in force under the Human Medicines Regulations 2012.

Please send any comments or objections to bpcom@mhra.gov.uk 

The deadline for response is 28 February 2025.